Viewing Study NCT05229068

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:47 PM
Ignite Modification Date: 2026-01-04 @ 8:03 PM
Study NCT ID: NCT05229068
Status: WITHDRAWN
Last Update Posted: 2022-04-07
First Post: 2022-01-27
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Respiratory Syncytial Virus Infections View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Respiratory Syncytial Virus Maternal vaccine View
None Safety View
None Reactogenicity View
None Immunogenicity View
None Healthy pregnant women View
None Subsequent pregnancy View